Jazz Pharmaceuticals plc (JAZZ) Stock Overview
Explore Jazz Pharmaceuticals plc’s financial performance, market position, analyst ratings, and future outlook.
Jazz Pharmaceuticals plc (JAZZ)
Key Financials
Key Financials
Market Cap
16.4B
P/E Ratio
17.05
EPS (TTM)
$12.86
ROE
0.21%
JAZZ Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Jazz Pharmaceuticals plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of JAZZ on the NASDAQ shows an RSI of 64.24, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $152.40 for the NASDAQ listing.
Key metrics behind Jazz Pharmaceuticals plc's NASDAQ-traded stock include a P/E ratio of 17.05 and a market capitalization of 16.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of JAZZ on the NASDAQ.